Loading clinical trials...
Loading clinical trials...
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES101 in Patients With Advanced Solid Tumors
Conditions
Interventions
ES101
Locations
1
China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Start Date
June 28, 2019
Primary Completion Date
April 22, 2022
Completion Date
April 22, 2022
Last Updated
April 29, 2022
NCT06898450
NCT00026884
NCT07169851
NCT07159659
NCT07213804
NCT06658951
Lead Sponsor
Elpiscience Biopharma, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions